Fractyl Health Wins European Clearance for First GLP-1 Gene Therapy Clinical Trial, Aiming to Replace Daily Injections With a One-Time Pancreas Edit
Fractyl Health received authorization in the Netherlands to run the world's first clinical trial of an AAV-based GLP-1 gene therapy for type 2 diabetes, targeting patients who cannot sustain daily injections.
6 min read4 sources